Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
What's in the Cards for Glaxo (GSK) This Earnings Season?

Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

MRK : 58.83 (+0.32%)
NVS : 77.88 (-1.42%)
PFE : 36.63 (+0.27%)
GSK : 40.00 (+0.30%)
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

MRK : 58.83 (+0.32%)
LLY : 79.06 (-0.87%)
INCY : 68.43 (-0.90%)
PFE : 36.63 (+0.27%)
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

XLV : 82.09 (-0.53%)
VHT : 155.13 (-0.47%)
JNJ : 126.66 (-0.70%)
IYH : 173.92 (-0.50%)
PFE : 36.63 (+0.27%)
UNH : 235.06 (-0.30%)
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

AZN : 35.34 (-0.17%)
RHHBY : 27.7350 (-0.48%)
PFE : 36.63 (+0.27%)
BMY : 51.17 (-0.85%)
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

XLV : 82.09 (-0.53%)
VHT : 155.13 (-0.47%)
JNJ : 126.66 (-0.70%)
IYH : 173.92 (-0.50%)
PFE : 36.63 (+0.27%)
UNH : 235.06 (-0.30%)
Model N Founder & CEO Zack Rinat Named Ernst & Young 2018 Entrepreneur of the Year Semifinalist

Model N, Inc. (NYSE: MODN), the leading provider of revenue management solutions for the pharmaceutical, medical device, high tech, manufacturing and semiconductor industries, announced that...

ABT : 59.19 (-1.15%)
AZN : 35.34 (-0.17%)
STX : 59.64 (-0.43%)
NXPI : 105.15 (-1.88%)
MODN : 17.65 (unch)
AMD : 9.99 (-1.19%)
MU : 50.62 (-1.56%)
GILD : 73.70 (-0.99%)
STM : 21.50 (-1.69%)
PFE : 36.63 (+0.27%)
SNY : 39.96 (-0.50%)
3 Dividend ETFs With High Inflows in April

Consider these three dividend ETFs to fend off growing market uncertainty.

MSFT : 95.00 (-1.15%)
VIG : 101.47 (-0.90%)
JPM : 111.47 (-0.22%)
INTC : 51.53 (-1.32%)
JNJ : 126.66 (-0.70%)
XOM : 79.00 (-0.53%)
SCHD : 48.65 (-0.98%)
VYM : 83.13 (-0.62%)
PFE : 36.63 (+0.27%)
WMT : 86.98 (-1.04%)
3 Dividend ETFs With High Inflows in April

Consider these three dividend ETFs to fend off growing market uncertainty.

MSFT : 95.00 (-1.15%)
VIG : 101.47 (-0.90%)
JPM : 111.47 (-0.22%)
INTC : 51.53 (-1.32%)
JNJ : 126.66 (-0.70%)
XOM : 79.00 (-0.53%)
SCHD : 48.65 (-0.98%)
VYM : 83.13 (-0.62%)
PFE : 36.63 (+0.27%)
WMT : 86.98 (-1.04%)
A.M. Best Affirms Credit Ratings of Blue Whale Re Ltd.

A.M. Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these...

PFE : 36.63 (+0.27%)
5 Drug Stocks Poised to Surpass on Earnings This Quarter

The outlook for the upcoming first-quarter results looks bright.

CTLT : 41.88 (-0.02%)
LLY : 79.06 (-0.87%)
ABBV : 92.60 (-0.44%)
PETX : 5.08 (+2.21%)
PFE : 36.63 (+0.27%)
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better

Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.

JNJ : 126.66 (-0.70%)
MRK : 58.83 (+0.32%)
PFE : 36.63 (+0.27%)
BMY : 51.17 (-0.85%)
What's in Store for Novartis (NVS) This Earnings Season?

We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.

NVS : 77.88 (-1.42%)
RHHBY : 27.7350 (-0.48%)
AMGN : 171.56 (-0.79%)
PFE : 36.63 (+0.27%)
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

JNJ : 126.66 (-0.70%)
MRK : 58.83 (+0.32%)
ABBV : 92.60 (-0.44%)
PFE : 36.63 (+0.27%)
Shire Sells Oncology Unit Ahead of Takeda's Potential Offer

Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.

TKPYY : 22.2200 (-5.93%)
SHPG : 164.37 (+2.26%)
ABBV : 92.60 (-0.44%)
PFE : 36.63 (+0.27%)
Pfizer Inc (PFE) Approaches New Upside Target of $36.69

Shares of Pfizer Inc (NYSE:PFE) opened today above their pivot of $36.32 and have already reached the first level of resistance at $36.50. Investors may be interested in a cross of the next upside pivot...

PFE : 36.63 (+0.27%)
Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD),...

FOLD : 14.21 (-2.94%)
NAVI : 13.28 (+0.38%)
SYY : 61.15 (-0.70%)
RAD : 1.58 (-1.25%)
PUMP : 18.81 (-0.21%)
PFE : 36.63 (+0.27%)
Latest Update to Chainbridge Transfer Pricing Issue in District of Columbia

The three taxpayers cited in our release dated February 12, 2018 have recently reached a tentative settlement agreement with the District of Columbia Office of Tax and Revenue (OTR). The administrative...

PFE : 36.63 (+0.27%)
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program....

MRK : 58.83 (+0.32%)
NVS : 77.88 (-1.42%)
ABBV : 92.60 (-0.44%)
PCRX : 36.00 (+1.55%)
PFE : 36.63 (+0.27%)
GSK : 40.00 (+0.30%)
BMY : 51.17 (-0.85%)
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug

Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.

ONCE : 81.39 (+0.28%)
SRPT : 79.99 (+1.83%)
BMRN : 82.30 (-1.58%)
PFE : 36.63 (+0.27%)
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus

With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their...

QURE : 32.21 (+2.35%)
ONCE : 81.39 (+0.28%)
BMRN : 82.30 (-1.58%)
NVS : 77.88 (-1.42%)
PFE : 36.63 (+0.27%)
AVXS : 206.48 (-1.07%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR +1.14 , HFC +0.02 , ABMD -0.53 , CAR -1.46 , URBN -1.09
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures closed the Friday session with 4 3/4 to 5 1/2 cent losses. Front month May was down 2.52% since last Friday. Friday’s CFTC Commitment of Traders report indicated spec funds in corn futures and options trimming their net long positi...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar